| INDIVIOR PHARMACEUTICALS |
| USA |
| Gesundheit |
| US45579U1097 / A42086 |
| E7P (Frankfurt) / INDV (NASDAQ) |
| FRA:E7P, ETR:E7P, E7P:GR, NASDAQ:INDV |
| - |
| https://www.indivior.com/ |
|
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on medicines for opioid use disorder and related substance use disorders. The company develops, manufactures, and markets buprenorphine-based prescription treatments designe..
>Volltext.. |
| 3525.85 Mio. EUR |
| 3777.37 Mio. EUR |
| 1154.5 Mio. EUR |
| 475.84 Mio. EUR |
| 307.69 Mio. EUR |
| 2.51 EUR |
| 441.17 Mio. EUR |
| 192.42 Mio. EUR |
| -42.16 Mio. EUR |
| 0.26 |
| 17.13% |
| 311.43% |
| - |
| - |
| - |
| 16.06.16 - 2.0083€ 17.09.15 - 0.67648€ |
| INDIVIOR |
| 17.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|